{"protocolSection": {"identificationModule": {"nctId": "NCT00570739", "orgStudyIdInfo": {"id": "WEL-411"}, "secondaryIdInfos": [{"id": "IND 68,466"}], "organization": {"fullName": "Daiichi Sankyo", "class": "INDUSTRY"}, "briefTitle": "Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.", "officialTitle": "Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug na\u00efve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes"}, "statusModule": {"statusVerifiedDate": "2010-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-11"}, "primaryCompletionDateStruct": {"date": "2009-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-10", "studyFirstSubmitQcDate": "2007-12-10", "studyFirstPostDateStruct": {"date": "2007-12-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-04-06", "resultsFirstSubmitQcDate": "2010-07-12", "resultsFirstPostDateStruct": {"date": "2010-07-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2010-07-19", "lastUpdatePostDateStruct": {"date": "2010-07-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Michael Jones, Sr. Director, Medical Affairs", "oldOrganization": "Daiichi Sankyo, Inc."}, "leadSponsor": {"name": "Daiichi Sankyo", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects. Diabetic participants will also be treated with open label, background,metformin HCl. Two-hundred sixty subjects with type 2 diabetes (T2DM) and 200 pre-diabetic subjects are planned to be be enrolled. Qualified subjects with T2DM will be randomized 1:1 to receive metformin HCl plus colesevelam HCl or metformin HCl plus placebo matching colesevelam HCl. Qualified pre-diabetic subjects will be randomized 1:1 to receive colesevelam HCl or matching placebo."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus", "Hypercholesterolemia", "Pre-diabetes"], "keywords": ["Colesevelam", "Type 2 Diabetes Mellitus", "Pre-diabetes", "Metformin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 502, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Diabetic Participants: Metformin HCl+Placebo for Colesevelam", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.", "interventionNames": ["Drug: Metformin HCl and Colesevelam Placebo"]}, {"label": "Diabetic participants: Metformin HCl + Colesevelam", "type": "EXPERIMENTAL", "description": "Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.", "interventionNames": ["Drug: Metformin HCl tablets and Colesevelam tablets"]}, {"label": "Pre-diabetic Participants: Colesevelam Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.", "interventionNames": ["Drug: Colesevelam placebo"]}, {"label": "Pre-diabetes Participants: Colesevelam", "type": "EXPERIMENTAL", "description": "Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.", "interventionNames": ["Drug: Colesevelam"]}], "interventions": [{"type": "DRUG", "name": "Metformin HCl and Colesevelam Placebo", "description": "One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks", "armGroupLabels": ["Diabetic Participants: Metformin HCl+Placebo for Colesevelam"]}, {"type": "DRUG", "name": "Metformin HCl tablets and Colesevelam tablets", "description": "One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks", "armGroupLabels": ["Diabetic participants: Metformin HCl + Colesevelam"]}, {"type": "DRUG", "name": "Colesevelam placebo", "description": "Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks", "armGroupLabels": ["Pre-diabetic Participants: Colesevelam Placebo"]}, {"type": "DRUG", "name": "Colesevelam", "description": "Six colesevelam 625 mg tablets will be given once a day for 16 weeks.", "armGroupLabels": ["Pre-diabetes Participants: Colesevelam"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-na\u00efve, Diabetic Subjects.", "timeFrame": "Baseline to 16 weeks"}, {"measure": "Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}], "secondaryOutcomes": [{"measure": "Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks"}, {"measure": "Fasting Plasma Glucose When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks"}, {"measure": "Fasting Insulin When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks"}, {"measure": "Fasting C-Peptide Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "30 Minute Post-Meal Glucose Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "1 Hour Post-Meal Glucose Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "2 Hour Post-Meal Glucose Levels to in Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "2 Hour Post-Meal Insulin Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "2 Hour Post-Meal C-Peptide Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of Total Cholesterol (TC) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of Triglycerides (TG)When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of Apolipoprotein B (Apo B)When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 weeks"}, {"measure": "Change in the Levels of Various Lipoprotein Particles When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 weeks"}, {"measure": "Change in the Size of Various Lipoprotein Particles When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change in the Calculated Total Triglycerides When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent of Subjects Achieving HbA1c Goal of <7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was > or = to 7.0% When Given to Drug-na\u00efve, Diabetics", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks"}, {"measure": "Percent of Subject Achieving HbA1c Goal of <6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-na\u00efve, Diabetic Subjects", "timeFrame": "Baseline to 4, 8, 12 and 16 weeks"}, {"measure": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 When Given to Drug-na\u00efve, Diabetic Subjects", "timeFrame": "Baseline to Weeks 8, and 16"}, {"measure": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of <70 mg/dL at Weeks 8, 16 When Given as to Drug-na\u00efve, Diabetics", "timeFrame": "Baseline to Weeks 8, and 16"}, {"measure": "Change in Body Weight When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT", "timeFrame": "Baseline vs. 16 Weeks"}, {"measure": "Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-na\u00efve, Diabetic From Baseline to 16 Weeks Subjects", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of <180 mg/dL When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to Week 16", "timeFrame": "Baseline to Week 16"}, {"measure": "Percent of Subjects Achieving Hs-C-Reactive Protein Goal of <2.0 mg/L When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline 16 Weeks"}, {"measure": "Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks"}, {"measure": "Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks"}, {"measure": "Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks"}, {"measure": "Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects", "timeFrame": "Baseline to 8, and 16 Weeks"}, {"measure": "Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent Achievement of <140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was >or= to 140 mg/dL From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent Achievement of <110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks"}, {"measure": "Percent Achievement of <100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks", "timeFrame": "Baseline to 4, 8, 12 and 16 weeks"}, {"measure": "Percent Achievement of <140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose <110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent Achievement of Hs-C-Reactive Protein <2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 2.0 mg/L From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}, {"measure": "Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "timeFrame": "Baseline to 16 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 to 79 years, inclusive.\n* HbA1C in the range of greater than or equal to 6.5 percent to small than or equal to 10.0 percent, to be enrolled in the T2DM cohort.\n* 2-hour post 75 g OGTT glucose levels in the range of:\n\n  * greater than or equal to 200 mg/dL to be enrolled in the T2DM cohort, or\n  * greater than or equal to 140 to 200 mg/dL to be enrolled in the pre-diabetes cohort.\n* FPG levels in the range of:\n\n  * greater than or equal to 126 mg/dL to be enrolled in the T2DM cohort, or\n  * greater than or equal to 110 to smaller than or equal to 125 mg/dL to be enrolled in the pre-diabetes cohort.\n* LDL-C levels greater than or equal to 100 mg/dL.\n* Drug-na\u00efve, defined as having never received treatment for T2DM or not having received antidiabetic drug therapy during the 3 months prior to screening visit.\n* Previous diagnosis of:\n\n  * T2DM or prediabetes, to be enrolled in the respective cohorts, or\n  * CHD, CVD, and/or primary hypercholesterolemia + BMI greater than or equal to 25 mg/kg2 to be screened for T2DM or pre-diabetes.\n* Understanding of the study procedures and agreement to participate in the study by giving written informed consent at screening visit.\n* Women may be enrolled if all 3 of the following criteria (in addition to the above criteria)are met:\n\n  * They are not pregnant (women of childbearing potential must have a negative serum pregnancy test \\[serum beta human chorionic gonadotropin )\\] at screening visit);\n  * They are not breast-feeding; and\n  * They do not plan to become pregnant during the study.\n* In addition to all of the above criteria, women must also meet 1 of the following 3 criteria to be enrolled:\n\n  * They have been post-menopausal for at least 1 year; or\n  * They are of childbearing potential and will practice 1 of the following methods of birth control throughout the study: oral, injectable, or implantable hormonal contraceptives; intrauterine device; diaphragm plus spermicide; or female condom plus spermicide. Methods of contraception that are not acceptable are partner's use of condoms or partner's vasectomy.\n\nExclusion Criteria:\n\n* History of type 1 diabetes and/or history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.\n* History of chronic (requiring daily for greater than 2 months) use of insulin therapy, except for the treatment of gestational diabetes.\n* Current or prior (within the past 3 months) treatment with an oral antidiabetic drug.\n* Current or prior (within the past 3 months) treatment with colesevelam HCl (WelChol), colestipol, colestimide, or cholestyramine.\n* History of dysphagia, swallowing disorders, or intestinal motility disorder.\n* Any serious disorder, including pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases, that would interfere with the conduct of the study or interpretation of the data.\n* Acute coronary syndrome (eg, myocardial infarction or unstable angina), coronary intervention (coronary artery bypass graft or percutaneous transluminal coronary angioplasty or similar procedure), congestive heart failure (requiring pharmacological treatment), or transient ischemic attack within 3 months of screening visit.\n* History of pancreatitis.\n* History of acquired immune deficiency syndrome or human immunodeficiency virus.\n* History of drug or alcohol abuse within the past 2 years.\n* Hospitalization for any cause within 14 days prior to screening visit.\n* History of an allergic or toxic response to colesevelam HCl or any of its components.\n* Known hypersensitivity to metformin HCl.\n* Serum TG greater than or equal to 500 mg/dL.\n* Body mass index (BMI) greater than 40 kg/m2 .", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Michael Jones", "affiliation": "DSI", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Birmingham", "state": "Alabama", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"city": "Los Gatos", "state": "California", "country": "United States", "geoPoint": {"lat": 37.22661, "lon": -121.97468}}, {"city": "Tarzana", "state": "California", "country": "United States", "geoPoint": {"lat": 34.17334, "lon": -118.55397}}, {"city": "Ocala", "state": "Florida", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"city": "Pocatello", "state": "Idaho", "country": "United States", "geoPoint": {"lat": 42.8713, "lon": -112.44553}}, {"city": "Gary", "state": "Indiana", "country": "United States", "geoPoint": {"lat": 41.59337, "lon": -87.34643}}, {"city": "New Orleans", "state": "Louisiana", "zip": "70112", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"city": "Olive Branch", "state": "Mississippi", "country": "United States", "geoPoint": {"lat": 34.96176, "lon": -89.82953}}, {"city": "Dundee", "state": "New York", "country": "United States", "geoPoint": {"lat": 42.5234, "lon": -76.97663}}, {"city": "West Seneca", "state": "New York", "country": "United States", "geoPoint": {"lat": 42.85006, "lon": -78.79975}}, {"city": "Statesville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.78264, "lon": -80.8873}}, {"city": "Kent", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 41.15367, "lon": -81.35789}}, {"city": "Marion", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 40.58867, "lon": -83.12852}}, {"city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"city": "Corpus Christi", "state": "Texas", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"city": "Barranquilla", "state": "Atl\u00e1ntico", "country": "Colombia", "geoPoint": {"lat": 10.96854, "lon": -74.78132}}, {"city": "Bogota", "state": "Cundinamarca", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"city": "Bucaramanga", "state": "Santander", "country": "Colombia", "geoPoint": {"lat": 7.12539, "lon": -73.1198}}, {"city": "Mumbai", "state": "Dadar", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"city": "Durgapura", "state": "Jaipur", "country": "India"}, {"city": "Bangalore", "state": "Karnataka", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"city": "Cochin", "state": "Kerala", "country": "India", "geoPoint": {"lat": 9.93988, "lon": 76.26022}}, {"city": "Nasik", "state": "Mah\u0101r\u0101shtra", "country": "India"}, {"city": "Las Palmas", "state": "Chihuahua", "country": "Mexico", "geoPoint": {"lat": 22.93672, "lon": -109.94235}}, {"city": "Delegacion", "state": "Cuauhtemoc", "country": "Mexico"}, {"city": "Guadalajara", "state": "Jalisco", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"city": "Monterrey", "state": "Nuevo Leon", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"city": "Hermosillo", "state": "Sonora", "country": "Mexico", "geoPoint": {"lat": 29.1026, "lon": -110.97732}}, {"city": "Merida", "state": "Yucatan", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}]}, "referencesModule": {"references": [{"pmid": "22913890", "type": "DERIVED", "citation": "Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones MR. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul;124(4):14-20. doi: 10.3810/pgm.2012.07.2564."}, {"pmid": "22836068", "type": "DERIVED", "citation": "Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol. 2012 Jul-Aug;6(4):318-24. doi: 10.1016/j.jacl.2012.05.005. Epub 2012 May 29."}, {"pmid": "20634176", "type": "DERIVED", "citation": "Handelsman Y, Goldberg RB, Garvey WT, Fonseca VA, Rosenstock J, Jones MR, Lai YL, Jin X, Misir S, Nagendran S, Abby SL. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug;16(4):617-28. doi: 10.4158/EP10129.OR."}, {"pmid": "20634175", "type": "DERIVED", "citation": "Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, Lai YL, Jin X, Misir S, Nagendran S, Jones MR. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug;16(4):629-40. doi: 10.4158/EP10130.OR."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Due to the different metabolic nature of the two groups the \"Total\" column under Baseline Characteristics is populated with data for the diabetic group, except where the total could be obtained by just adding the number of participants. Please note: in the outcomes section, LOCF=Last Observation carried forward", "recruitmentDetails": "Two cohorts of participants, type 2 diabetics (T2DM) and pre-diabetics, were recruited from 07 Jan 2008 to 15 Dec 2008. The sites were located in Colombia, India, Mexico, and the USA. The sites included private physician offices, group practices, clinics, hospitals, institutes, and university centers.", "groups": [{"id": "FG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks."}, {"id": "FG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 16 weeks."}, {"id": "FG002", "title": "Pre-diabetic Group: Placebo", "description": "This group was given 6 placebo tablets once a day. They matched the colesevelam tablets. This treatment duration was 16 weeks."}, {"id": "FG003", "title": "Pre-diabetic Group: Colesevelam", "description": "This group was given 6 colesevelam tablets, 625mg, once a day. This treatment duration was 16 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "141"}, {"groupId": "FG001", "numSubjects": "145"}, {"groupId": "FG002", "numSubjects": "108"}, {"groupId": "FG003", "numSubjects": "108"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "120"}, {"groupId": "FG001", "numSubjects": "124"}, {"groupId": "FG002", "numSubjects": "92"}, {"groupId": "FG003", "numSubjects": "96"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Required restricted medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Met discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks."}, {"id": "BG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 16 weeks."}, {"id": "BG002", "title": "Pre-diabetic Group: Placebo", "description": "This group received 6 colesevelam matching placebo tablets once per day for 16 weeks"}, {"id": "BG003", "title": "Pre-diabetic Group: Colesevelam", "description": "This group received 6 colesevelam tablets, 625mg, once per day for 16 weeks."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "108"}, {"groupId": "BG003", "value": "108"}, {"groupId": "BG004", "value": "502"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.9", "spread": "10.11"}, {"groupId": "BG001", "value": "52.7", "spread": "11.46"}, {"groupId": "BG002", "value": "55.7", "spread": "11.14"}, {"groupId": "BG003", "value": "53.3", "spread": "12.27"}, {"groupId": "BG004", "value": "53.3", "spread": "10.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "81"}, {"groupId": "BG003", "value": "68"}, {"groupId": "BG004", "value": "310"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "40"}, {"groupId": "BG004", "value": "192"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "91"}]}]}, {"title": "Black/African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "6"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "66"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "89"}, {"groupId": "BG002", "value": "78"}, {"groupId": "BG003", "value": "82"}, {"groupId": "BG004", "value": "339"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "93"}]}]}, {"title": "Mexico", "categories": [{"measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "41"}, {"groupId": "BG004", "value": "195"}]}]}, {"title": "Colombia", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "36"}, {"groupId": "BG003", "value": "37"}, {"groupId": "BG004", "value": "124"}]}]}, {"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "90"}]}]}]}, {"title": "Previously diagnosed with neither diabetes nor pre-diabetes", "paramType": "NUMBER", "unitOfMeasure": "Participant", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "26"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "77"}]}]}]}, {"title": "Previously diagnosed with pre-diabetes", "paramType": "NUMBER", "unitOfMeasure": "Participant", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "81"}, {"groupId": "BG003", "value": "85"}, {"groupId": "BG004", "value": "204"}]}]}]}, {"title": "Previously diagnosed with type 2 diabetes", "paramType": "NUMBER", "unitOfMeasure": "Participant", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "109"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "221"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m squared", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.78", "spread": "4.44"}, {"groupId": "BG001", "value": "30.58", "spread": "4.669"}, {"groupId": "BG002", "value": "30.82", "spread": "4.18"}, {"groupId": "BG003", "value": "30.93", "spread": "4.89"}, {"groupId": "BG004", "value": "30.19", "spread": "4.57"}]}]}]}, {"title": "Fasting glucose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "145.7", "spread": "37.54"}, {"groupId": "BG001", "value": "153.4", "spread": "39.04"}, {"groupId": "BG002", "value": "106.8", "spread": "14.80"}, {"groupId": "BG003", "value": "104.1", "spread": "11.33"}, {"groupId": "BG004", "value": "149.6", "spread": "38.43"}]}]}]}, {"title": "Fasting insulin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "uIU/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12.82", "spread": "8.44"}, {"groupId": "BG001", "value": "13.86", "spread": "15.75"}, {"groupId": "BG002", "value": "11.03", "spread": "5.55"}, {"groupId": "BG003", "value": "13.12", "spread": "8.75"}, {"groupId": "BG004", "value": "13.34", "spread": "12.66"}]}]}]}, {"title": "Glucose 2 hours after meal", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "220.3", "spread": "58.68"}, {"groupId": "BG001", "value": "234.7", "spread": "71.36"}, {"groupId": "BG002", "value": "153.7", "spread": "39.81"}, {"groupId": "BG003", "value": "153.7", "spread": "37.90"}, {"groupId": "BG004", "value": "227.7", "spread": "65.74"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "160.6", "spread": "10.64"}, {"groupId": "BG001", "value": "162.3", "spread": "9.67"}, {"groupId": "BG002", "value": "159.1", "spread": "9.95"}, {"groupId": "BG003", "value": "160.8", "spread": "9.96"}, {"groupId": "BG004", "value": "161.5", "spread": "10.18"}]}]}]}, {"title": "Hemoglobin A1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.53", "spread": "0.94"}, {"groupId": "BG001", "value": "7.76", "spread": "1.04"}, {"groupId": "BG002", "value": "6.07", "spread": "0.45"}, {"groupId": "BG003", "value": "6.02", "spread": "0.46"}, {"groupId": "BG004", "value": "7.65", "spread": "1.0"}]}]}]}, {"title": "Low Density Lipoprotein Cholesterol", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "135.5", "spread": "26.66"}, {"groupId": "BG001", "value": "129.1", "spread": "23.08"}, {"groupId": "BG002", "value": "136.8", "spread": "28.48"}, {"groupId": "BG003", "value": "132.8", "spread": "23.88"}, {"groupId": "BG004", "value": "132.2", "spread": "25.07"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "77.26", "spread": "16.17"}, {"groupId": "BG001", "value": "80.84", "spread": "15.53"}, {"groupId": "BG002", "value": "78.18", "spread": "13.76"}, {"groupId": "BG003", "value": "80.63", "spread": "18.02"}, {"groupId": "BG004", "value": "79.08", "spread": "15.92"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Percent Change in Hemoglobin A1C (HbA1C) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 4, 8, 12 and 16 Weeks.", "populationDescription": "The number analyzed equals the full analysis set. The full analysis set included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. This analysis set was used for the summary and analysis of all efficacy variables. LOCF was not used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change in HbA1c", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group:Placebo+Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group:Colesevelam+Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "Baseline to 4 weeks:Pla+Met, N=128, Col+Met N=129", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.044"}, {"groupId": "OG001", "value": "-0.53", "spread": "0.044"}]}]}, {"title": "Baseline to 8 weeks:Pla+Met, N=123, Col+Met N=125", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.67", "spread": "0.055"}, {"groupId": "OG001", "value": "-0.84", "spread": "0.055"}]}]}, {"title": "Baseline to 12 weeks:Pla+Met, N=115, Col+Met N=123", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "0.062"}, {"groupId": "OG001", "value": "-1.05", "spread": "0.059"}]}]}, {"title": "Baseline to 16 weeks:Pla+Met, N=118, Col+Met N=122", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.92", "spread": "0.064"}, {"groupId": "OG001", "value": "-1.17", "spread": "0.063"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0123", "pValueComment": "P-Value is for the LS mean difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.27", "ciUpperLimit": "-0.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0201", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.33", "ciUpperLimit": "-0.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0239", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.36", "ciUpperLimit": "-0.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0046", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.42", "ciUpperLimit": "-0.08"}]}, {"type": "SECONDARY", "title": "Fasting Plasma Glucose When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo+Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group:Colesevelam+Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "131"}]}], "classes": [{"title": "baseline to 4 weeks Pla+Met N=130, Col+Met N=131", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.0", "spread": "2.31"}, {"groupId": "OG001", "value": "-24.0", "spread": "2.30"}]}]}, {"title": "baseline to 8 weeks:Pla+Met N=122, Col+Met N=126", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.3", "spread": "1.97"}, {"groupId": "OG001", "value": "-27.6", "spread": "1.94"}]}]}, {"title": "baseline to 12 weeks:Pla+Met N=121, Col+Met N=125", "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.3", "spread": "2.21"}, {"groupId": "OG001", "value": "-28.4", "spread": "2.18"}]}]}, {"title": "baseline to 16 weeks:Pla+Met N=119, Col+Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.0", "spread": "2.21"}, {"groupId": "OG001", "value": "-30.5", "spread": "2.16"}]}]}, {"title": "baseline to 16wks LOCF:Pla+Met N=137,Col+Met N=138", "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.9", "spread": "2.19"}, {"groupId": "OG001", "value": "-28.0", "spread": "2.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1112", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.3", "ciUpperLimit": "1.2"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2167", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.6", "ciUpperLimit": "2.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7269", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.0", "ciUpperLimit": "4.9"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4063", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.4", "ciUpperLimit": "3.4"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks (LOCF)", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4909", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.0", "ciUpperLimit": "3.9"}]}, {"type": "SECONDARY", "title": "Fasting Insulin When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "uIU/mL", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group:Placebo+Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group:Colesevelam+Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"title": "Baseline to 4 weeks:Pla+Met, N=127, Col+Met N=127", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.124", "spread": "0.7219"}, {"groupId": "OG001", "value": "-2.427", "spread": "0.7219"}]}]}, {"title": "Baseline to 8 weeks:Pla+Met, N=124, Col+Met N=126", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.992", "spread": "0.5407"}, {"groupId": "OG001", "value": "-3.007", "spread": "0.5376"}]}]}, {"title": "Baseline to 12 weeks:Pla+Met, N=117, Col+Met N=123", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.204", "spread": "0.5159"}, {"groupId": "OG001", "value": "-3.708", "spread": "0.5048"}]}]}, {"title": "Baseline to 16 weeks:Pla+Met, N=119, Col+Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.978", "spread": "0.7379"}, {"groupId": "OG001", "value": "-2.802", "spread": "0.7217"}]}]}, {"title": "Baseline to16wks LOCF:Pla+Met,N=137,Col+Met N=138", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.847", "spread": "0.6655"}, {"groupId": "OG001", "value": "-2.637", "spread": "0.6644"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7606", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.303", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.259", "ciUpperLimit": "1.653"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1782", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.477", "ciUpperLimit": "0.447"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0332", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.504", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.887", "ciUpperLimit": "-0.121"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8610", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.176", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.805", "ciUpperLimit": "2.158"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks (LOCF)", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8196", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.210", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.599", "ciUpperLimit": "2.019"}]}, {"type": "SECONDARY", "title": "Fasting C-Peptide Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.295", "spread": "0.0695"}, {"groupId": "OG001", "value": "-0.449", "spread": "0.0683"}]}]}, {"title": "Baseline to 16Wks LOCF Pla+Met N=133,Col+Met N=134", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.284", "spread": "0.0650"}, {"groupId": "OG001", "value": "-0.426", "spread": "0.0644"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1078", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.153", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.340", "ciUpperLimit": "0.034"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks (LOCF)", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1146", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.141", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.317", "ciUpperLimit": "0.035"}]}, {"type": "SECONDARY", "title": "30 Minute Post-Meal Glucose Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"title": "Baseline to 16 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-33.1", "spread": "3.46"}, {"groupId": "OG001", "value": "-33.1", "spread": "3.43"}]}]}, {"title": "Baseline to 16Wks LOCF Pla+Met N=133,Col+Met N=132", "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.4", "spread": "3.44"}, {"groupId": "OG001", "value": "-30.4", "spread": "3.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9933", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.3", "ciUpperLimit": "9.4"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8203", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.5", "ciUpperLimit": "8.3"}]}, {"type": "SECONDARY", "title": "1 Hour Post-Meal Glucose Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.0", "spread": "3.91"}, {"groupId": "OG001", "value": "-41.9", "spread": "3.88"}]}]}, {"title": "Baseline to 16 Weeks LOCF:N=131 Pla; N=129 Colesev", "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.4", "spread": "3.92"}, {"groupId": "OG001", "value": "-39.1", "spread": "3.94"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1950", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.5", "ciUpperLimit": "3.6"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1583", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.3", "ciUpperLimit": "3.0"}]}, {"type": "SECONDARY", "title": "2 Hour Post-Meal Glucose Levels to in Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-33.0", "spread": "4.11"}, {"groupId": "OG001", "value": "-38.14", "spread": "4.02"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=129, Met N=127", "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.4", "spread": "4.18"}, {"groupId": "OG001", "value": "-36.2", "spread": "4.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3663", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.1", "ciUpperLimit": "6.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2524", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.9", "ciUpperLimit": "4.7"}]}, {"type": "SECONDARY", "title": "2 Hour Post-Meal Insulin Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "uIU/mL", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "116"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.601", "spread": "3.2794"}, {"groupId": "OG001", "value": "-10.551", "spread": "3.2370"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=129, Met N=127", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.592", "spread": "3.4395"}, {"groupId": "OG001", "value": "-10.156", "spread": "3.4399"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8158", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.051", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.828", "ciUpperLimit": "9.929"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7433", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.565", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.966", "ciUpperLimit": "7.836"}]}, {"type": "SECONDARY", "title": "2 Hour Post-Meal C-Peptide Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed = the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Results are presented for both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "121"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.317", "spread": "0.2424"}, {"groupId": "OG001", "value": "-0.102", "spread": "0.2373"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=129, Met N=130", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.205", "spread": "0.2406"}, {"groupId": "OG001", "value": "-0.135", "spread": "0.2374"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5161", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.215", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.437", "ciUpperLimit": "0.867"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8319", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups.", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.070", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.581", "ciUpperLimit": "0.722"}]}, {"type": "SECONDARY", "title": "The Percent Change of Low Density Lipoprotein Cholesterol (LDL-C) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of change in LDL-C", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam+Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.83", "spread": "1.631"}, {"groupId": "OG001", "value": "-24.01", "spread": "1.614"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=119, Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.94", "spread": "1.852"}, {"groupId": "OG001", "value": "-22.02", "spread": "1.813"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=137, Met N=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.11", "spread": "1.695"}, {"groupId": "OG001", "value": "-21.44", "spread": "1.700"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.61", "ciUpperLimit": "-13.76"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-17.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.09", "ciUpperLimit": "-12.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-16.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.96", "ciUpperLimit": "-11.69"}]}, {"type": "SECONDARY", "title": "Percent Change of Non-High Density Lipoprotein (Non-HDL) Levels When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of change in non-HDL", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.79", "spread": "1.327"}, {"groupId": "OG001", "value": "-18.19", "spread": "1.316"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=119, Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.08", "spread": "1.460"}, {"groupId": "OG001", "value": "-14.36", "spread": "1.436"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=137, Met N=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.38", "spread": "1.338"}, {"groupId": "OG001", "value": "-13.70", "spread": "1.346"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-12.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.99", "ciUpperLimit": "-8.81"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.23", "ciUpperLimit": "-5.34"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Week LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.98", "ciUpperLimit": "-4.67"}]}, {"type": "SECONDARY", "title": "Percent Change of High Density Lipoprotein Cholesterol(HDL-C) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.98", "spread": "1.506"}, {"groupId": "OG001", "value": "5.61", "spread": "1.488"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=119, Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.46", "spread": "1.277"}, {"groupId": "OG001", "value": "8.78", "spread": "1.250"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=137, Met N=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.58", "spread": "1.160"}, {"groupId": "OG001", "value": "8.39", "spread": "1.165"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2026", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Median Difference (Final Values)", "paramValue": "2.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.43", "ciUpperLimit": "6.70"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4506", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.12", "ciUpperLimit": "4.75"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2609", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "1.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.35", "ciUpperLimit": "4.97"}]}, {"type": "SECONDARY", "title": "Percent Change of Total Cholesterol (TC) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change of TC", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.46", "spread": "1.009"}, {"groupId": "OG001", "value": "-13.26", "spread": "1.000"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=119, Met=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.85", "spread": "1.217"}, {"groupId": "OG001", "value": "-9.79", "spread": "1.197"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=137, Met=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.22", "spread": "1.115"}, {"groupId": "OG001", "value": "-9.31", "spread": "1.121"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.53", "ciUpperLimit": "-6.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.23", "ciUpperLimit": "-3.66"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.14", "ciUpperLimit": "-3.05"}]}, {"type": "SECONDARY", "title": "Percent Change of Triglycerides (TG)When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Percentage of change of TG", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.39", "lowerLimit": "-11.41", "upperLimit": "0.58"}, {"groupId": "OG001", "value": "1.28", "lowerLimit": "-4.48", "upperLimit": "5.58"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=119, Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.12", "lowerLimit": "-25.58", "upperLimit": "7.32"}, {"groupId": "OG001", "value": "8.63", "lowerLimit": "-8.74", "upperLimit": "36.85"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=137, Met N=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.55", "lowerLimit": "-24.13", "upperLimit": "14.40"}, {"groupId": "OG001", "value": "8.80", "lowerLimit": "6.25", "upperLimit": "15.88"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0171", "pValueComment": "The P-Value was from the non-parametric ANCOVA stratified by country.", "statisticalMethod": "ANCOVA", "statisticalComment": "The median difference was calculated using Hodges-Lehmann point estimate and corresponding 95% CI was constructed using the method of Moses.", "paramType": "Mean Difference (Final Values)", "paramValue": "7.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.33", "ciUpperLimit": "13.99"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The P-Value was from the non-parametric ANCOVA stratified by country.", "statisticalMethod": "ANCOVA", "statisticalComment": "The median difference was calculated using Hodges-Lehmann point estimate and corresponding 95% CI was constructed using the method of Moses.", "paramType": "Mean Difference (Final Values)", "paramValue": "17.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.66", "ciUpperLimit": "25.54"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The P-Value was from the non-parametric ANCOVA stratified by country.", "statisticalMethod": "ANCOVA", "statisticalComment": "The median difference was calculated using Hodges-Lehmann point estimate and corresponding 95% CI was constructed using the method of Moses.", "paramType": "Mean Difference (Final Values)", "paramValue": "18.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "11.18", "ciUpperLimit": "25.74"}]}, {"type": "SECONDARY", "title": "Percent Change of Apolipoprotein A-1 (Apo A-1) When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change in Apo A-1", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.30", "spread": "1.047"}, {"groupId": "OG001", "value": "6.12", "spread": "1.027"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=113, Met N=120", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.86", "spread": "1.052"}, {"groupId": "OG001", "value": "8.51", "spread": "1.024"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=133, Met N=134", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.02", "spread": "0.957"}, {"groupId": "OG001", "value": "8.45", "spread": "0.953"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0496", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "2.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0", "ciUpperLimit": "5.62"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0117", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "3.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.82", "ciUpperLimit": "6.47"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0009", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "4.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.83", "ciUpperLimit": "7.03"}]}, {"type": "SECONDARY", "title": "Percent Change of Apolipoprotein B (Apo B)When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change in Apo B", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.59", "spread": "1.184"}, {"groupId": "OG001", "value": "16.15", "spread": "1.158"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=113, Met N=120", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.89", "spread": "1.340"}, {"groupId": "OG001", "value": "-13.42", "spread": "1.307"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=133, Met N=134", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.20", "spread": "1.242"}, {"groupId": "OG001", "value": "-12.17", "spread": "1.239"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.74", "ciUpperLimit": "-8.38"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.14", "ciUpperLimit": "-5.92"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.35", "ciUpperLimit": "-4.59"}]}, {"type": "SECONDARY", "title": "Percent Change of Apolipoprotein C3 (Apo C3)When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change in Apo C3", "timeFrame": "Baseline to 8, and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "2.527"}, {"groupId": "OG001", "value": "12.58", "spread": "2.495"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=117, Met N=120", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.06", "spread": "2.932"}, {"groupId": "OG001", "value": "18.58", "spread": "2.871"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=136, N=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.82", "spread": "2.621"}, {"groupId": "OG001", "value": "17.89", "spread": "2.620"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "12.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.76", "ciUpperLimit": "19.38"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "14.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.64", "ciUpperLimit": "22.40"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "15.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.95", "ciUpperLimit": "22.20"}]}, {"type": "SECONDARY", "title": "Change in the Levels of Various Lipoprotein Particles When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin for 16 Weeks", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}, {"id": "OG002", "title": "Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks (LOCF)", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG003", "title": "Type 2 Diabetes Group:Colesevelam+Metformin for 16 Weeks(LOCF)", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "133"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"title": "Total Very Low Density Lipoprotein (VLDL) Particle", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.03", "spread": "2.361"}, {"groupId": "OG001", "value": "2.81", "spread": "2.355"}, {"groupId": "OG002", "value": "-3.71", "spread": "2.167"}, {"groupId": "OG003", "value": "2.68", "spread": "2.188"}]}]}, {"title": "VLDL Chylomicron Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "0.554"}, {"groupId": "OG001", "value": "1.73", "spread": "0.552"}, {"groupId": "OG002", "value": "-0.58", "spread": "0.507"}, {"groupId": "OG003", "value": "1.76", "spread": "0.511"}]}]}, {"title": "Medium VLDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.31", "spread": "1.496"}, {"groupId": "OG001", "value": "4.84", "spread": "1.492"}, {"groupId": "OG002", "value": "-2.28", "spread": "1.383"}, {"groupId": "OG003", "value": "4.85", "spread": "1.396"}]}]}, {"title": "Small VLDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.12", "spread": "1.536"}, {"groupId": "OG001", "value": "-4.00", "spread": "1.532"}, {"groupId": "OG002", "value": "-0.83", "spread": "1.413"}, {"groupId": "OG003", "value": "-4.06", "spread": "1.426"}]}]}, {"title": "Total Low Density Lipoprotein (LDL) Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-104.0", "spread": "27.04"}, {"groupId": "OG001", "value": "-303.3", "spread": "27.05"}, {"groupId": "OG002", "value": "-109.5", "spread": "25.49"}, {"groupId": "OG003", "value": "-295.5", "spread": "25.77"}]}]}, {"title": "Intermediate Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.6", "spread": "4.24"}, {"groupId": "OG001", "value": "-21.3", "spread": "4.24"}, {"groupId": "OG002", "value": "-8.9", "spread": "4.03"}, {"groupId": "OG003", "value": "-19.6", "spread": "4.08"}]}]}, {"title": "Large LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.1", "spread": "15.74"}, {"groupId": "OG001", "value": "-25.5", "spread": "15.69"}, {"groupId": "OG002", "value": "45.1", "spread": "14.60"}, {"groupId": "OG003", "value": "-24.2", "spread": "14.73"}]}]}, {"title": "Small LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-146.9", "spread": "31.63"}, {"groupId": "OG001", "value": "-256.7", "spread": "31.63"}, {"groupId": "OG002", "value": "-145.9", "spread": "29.52"}, {"groupId": "OG003", "value": "-252.7", "spread": "29.84"}]}]}, {"title": "Medium Small LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-32.0", "spread": "7.16"}, {"groupId": "OG001", "value": "-48.2", "spread": "7.15"}, {"groupId": "OG002", "value": "-30.8", "spread": "6.72"}, {"groupId": "OG003", "value": "-46.2", "spread": "6.78"}]}]}, {"title": "Very Small LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-115.0", "spread": "24.96"}, {"groupId": "OG001", "value": "-208.7", "spread": "24.97"}, {"groupId": "OG002", "value": "-115.3", "spread": "23.31"}, {"groupId": "OG003", "value": "-206.6", "spread": "23.57"}]}]}, {"title": "Total High Density Lipoprotein (HDL) Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.47", "spread": "0.352"}, {"groupId": "OG001", "value": "2.41", "spread": "0.351"}, {"groupId": "OG002", "value": "1.34", "spread": "0.332"}, {"groupId": "OG003", "value": "2.35", "spread": "0.335"}]}]}, {"title": "Large HDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.64", "spread": "0.160"}, {"groupId": "OG001", "value": "1.09", "spread": "0.161"}, {"groupId": "OG002", "value": "0.55", "spread": "0.153"}, {"groupId": "OG003", "value": "1.00", "spread": "0.155"}]}]}, {"title": "Medium HDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "spread": "0.275"}, {"groupId": "OG001", "value": "0.50", "spread": "0.274"}, {"groupId": "OG002", "value": "-0.26", "spread": "0.259"}, {"groupId": "OG003", "value": "0.59", "spread": "0.261"}]}]}, {"title": "Small HDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.04", "spread": "0.385"}, {"groupId": "OG001", "value": "0.74", "spread": "0.384"}, {"groupId": "OG002", "value": "1.05", "spread": "0.362"}, {"groupId": "OG003", "value": "0.70", "spread": "0.366"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Total Very Low Density Lipoprotein (VLDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0363", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "6.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.44", "ciUpperLimit": "13.24"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Total Very Low Density Lipoprotein (VLDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0347", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "6.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "12.31"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "VLDL Chylomicron Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0028", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.80", "ciUpperLimit": "3.81"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "VLDL Chylomicron Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "3.73"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Medium VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "7.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.10", "ciUpperLimit": "11.21"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Medium VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "7.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.35", "ciUpperLimit": "10.91"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Small VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1750", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.04", "ciUpperLimit": "1.29"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Small VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1007", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.10", "ciUpperLimit": "0.63"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Total Low Density Lipoprotein (LDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-199.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-272.9", "ciUpperLimit": "-125.8"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Total Low Density Lipoprotein (LDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-186.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-255.9", "ciUpperLimit": "-116.3"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Intermediate Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0466", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.3", "ciUpperLimit": "-0.2"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Intermediate Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0570", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.8", "ciUpperLimit": "0.3"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Large LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Net)", "paramValue": "-77.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-120.3", "ciUpperLimit": "-35.0"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Large LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0007", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-69.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-109.2", "ciUpperLimit": "-29.3"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0124", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-109.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-195.8", "ciUpperLimit": "-23.9"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0098", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-106.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-187.6", "ciUpperLimit": "-26.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Medium Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1020", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-16.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.6", "ciUpperLimit": "3.2"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Medium Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0997", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-15.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.8", "ciUpperLimit": "3.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Very Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0069", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-93.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-161.6", "ciUpperLimit": "-25.9"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Very Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0052", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-91.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-155.2", "ciUpperLimit": "-27.5"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Total High Density Lipoprotein (HDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0524", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.01", "ciUpperLimit": "1.90"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Total High Density Lipoprotein (HDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0301", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "1.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.10", "ciUpperLimit": "1.91"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Large HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0416", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.02", "ciUpperLimit": "0.89"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Large HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0333", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "0.88"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Medium HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0693", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "1.44"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Medium HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0187", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "1.56"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Small HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5765", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.34", "ciUpperLimit": "0.75"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Small HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4762", "pValueComment": "P-Value is for the LS Mean Difference between treatment group", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.35", "ciUpperLimit": "0.63"}]}, {"type": "SECONDARY", "title": "Change in the Size of Various Lipoprotein Particles When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nm", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin for 16 Weeks", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}, {"id": "OG002", "title": "Type 2 Diabetes Group: Placebo + Metformin for 16 Weeks (LOCF)", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG003", "title": "Type 2 Diabetes Group:Colesevelam+Metformin for 16 Weeks(LOCF)", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "133"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"title": "Very Low Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.80", "spread": "0.868"}, {"groupId": "OG001", "value": "1.41", "spread": "0.866"}, {"groupId": "OG002", "value": "-1.02", "spread": "0.796"}, {"groupId": "OG003", "value": "1.73", "spread": "0.804"}]}]}, {"title": "Low Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "0.053"}, {"groupId": "OG001", "value": "0.15", "spread": "0.053"}, {"groupId": "OG002", "value": "0.19", "spread": "0.049"}, {"groupId": "OG003", "value": "0.15", "spread": "0.050"}]}]}, {"title": "High Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.023"}, {"groupId": "OG001", "value": "0.17", "spread": "0.023"}, {"groupId": "OG002", "value": "0.08", "spread": "0.021"}, {"groupId": "OG003", "value": "0.17", "spread": "0.022"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Very Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0652", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.14", "ciUpperLimit": "4.57"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Very Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0137", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "4.92"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Low Density Lipoprotien Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4726", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.20", "ciUpperLimit": "0.09"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5715", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.10"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "High Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0083", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.02", "ciUpperLimit": "0.15"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "High Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0022", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "0.15"}]}, {"type": "SECONDARY", "title": "Change in the Calculated Total Triglycerides When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.5", "spread": "6.44"}, {"groupId": "OG001", "value": "17.6", "spread": "6.43"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=133, Met N=129", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.0", "spread": "5.88"}, {"groupId": "OG001", "value": "18.2", "spread": "5.93"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0036", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "26.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.6", "ciUpperLimit": "43.5"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "27.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "11.2", "ciUpperLimit": "43.3"}]}, {"type": "SECONDARY", "title": "Change in the Calculated Very Low Density Lipoprotein Triglycerides When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.4", "spread": "6.36"}, {"groupId": "OG001", "value": "22.4", "spread": "6.34"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=133, Met N= 129", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.9", "spread": "5.81"}, {"groupId": "OG001", "value": "22.9", "spread": "5.86"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0008", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "29.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.5", "ciUpperLimit": "47.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "30.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "14.9", "ciUpperLimit": "46.6"}]}, {"type": "SECONDARY", "title": "Change in the Calculated High Density Lipoprotein Cholesterol When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "0.62"}, {"groupId": "OG001", "value": "5.8", "spread": "0.62"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=133, Met N=129", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "spread": "0.59"}, {"groupId": "OG001", "value": "5.6", "spread": "0.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0033", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.9", "ciUpperLimit": "4.3"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0008", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.2", "ciUpperLimit": "4.4"}]}, {"type": "PRIMARY", "title": "Percent Change of Hemoglobin A1C (HbA1C) From Baseline to 16 Weeks When Given as Initial Therapy to Drug-na\u00efve, Diabetic Subjects.", "populationDescription": "The number analyzed equals the full analysis set. The full analysis set included all randomized subjects who took at least 1 dose of randomized study medication, and had a baseline and at least 1 post-baseline efficacy variable measurement. This analysis set was used for the summary and analysis of all efficacy variables. LOCF was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change of hemoglobin A1C", "timeFrame": "Baseline to 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "138"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.064"}, {"groupId": "OG001", "value": "-1.09", "spread": "0.064"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0035", "pValueComment": "P-Value is for the LS mean difference between the treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The Ancova model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.44", "ciUpperLimit": "-0.09"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving HbA1c Goal of <7.0% at Weeks 4, 8, 12, and 16 if Baseline HbA1c Was > or = to 7.0% When Given to Drug-na\u00efve, Diabetics", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "93"}]}], "classes": [{"title": "Baseline to 4 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.1"}, {"groupId": "OG001", "value": "25.8"}]}]}, {"title": "Baseline to 8 Weeks: Pla N=87, Met N=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.1"}, {"groupId": "OG001", "value": "48.4"}]}]}, {"title": "Baseline to 12 Weeks: Pla N=79, Met N=89", "categories": [{"measurements": [{"groupId": "OG000", "value": "59.5"}, {"groupId": "OG001", "value": "64.0"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=83, Met N=87", "categories": [{"measurements": [{"groupId": "OG000", "value": "59.0"}, {"groupId": "OG001", "value": "72.4"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=95, Met N=99", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.8"}, {"groupId": "OG001", "value": "66.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5848", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country.", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8147", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4957", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0467", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0589", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country.", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0049", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.38", "ciUpperLimit": "6.10"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0092", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.25", "ciUpperLimit": "4.76"}]}, {"type": "SECONDARY", "title": "Percent of Subject Achieving HbA1c Goal of <6.5% at Weeks 4, 8, 12, and 16 When Given to Drug-na\u00efve, Diabetic Subjects", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of particpants", "timeFrame": "Baseline to 4, 8, 12 and 16 weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline to 4 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.0"}, {"groupId": "OG001", "value": "24.8"}]}]}, {"title": "Baseline to 8 Weeks: Pla N=118, Met N=121", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.7"}, {"groupId": "OG001", "value": "36.4"}]}]}, {"title": "Baseline to 12 Weeks: Pla N=110, Met N=119", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.2"}, {"groupId": "OG001", "value": "51.3"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=114, Met N=118", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.7"}, {"groupId": "OG001", "value": "55.9"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=131, Met N=134", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.2"}, {"groupId": "OG001", "value": "52.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0008", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Startified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0280", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0414", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0840", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0589", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0095", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.21", "ciUpperLimit": "3.96"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0088", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.20", "ciUpperLimit": "3.60"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 When Given to Drug-na\u00efve, Diabetic Subjects", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to Weeks 8, and 16", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "115"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.2"}, {"groupId": "OG001", "value": "54.8"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=114, Met N=116", "categories": [{"measurements": [{"groupId": "OG000", "value": "17.5"}, {"groupId": "OG001", "value": "50.0"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=131, Met N=127", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.3"}, {"groupId": "OG001", "value": "48.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "5.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.78", "ciUpperLimit": "11.23"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "4.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.53", "ciUpperLimit": "9.10"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol Goal of <70 mg/dL at Weeks 8, 16 When Given as to Drug-na\u00efve, Diabetics", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to Weeks 8, and 16", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.6"}, {"groupId": "OG001", "value": "13.7"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=119, Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0"}, {"groupId": "OG001", "value": "12.9"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=1137, Met N=136", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.4"}, {"groupId": "OG001", "value": "12.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0326", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0157", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Stratified by country", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0870", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "paramType": "Odds Ratio (OR)", "paramValue": "2.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "7.07"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.00439", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate.", "paramType": "Odds Ratio (OR)", "paramValue": "2.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.03", "ciUpperLimit": "7.94"}]}, {"type": "SECONDARY", "title": "Change in Body Weight When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "lb", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.11", "spread": "0.564"}, {"groupId": "OG001", "value": "-4.91", "spread": "0.552"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=134, Met N=134", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.71", "spread": "0.523"}, {"groupId": "OG001", "value": "-4.56", "spread": "0.519"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7959", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.32", "ciUpperLimit": "1.72"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8371", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.28", "ciUpperLimit": "1.57"}]}, {"type": "SECONDARY", "title": "Change in Waist-to-Hip Ratio When Given to Drug-Naive Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Ratio", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}, {"groupId": "OG001", "value": "124"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0033", "spread": "0.00329"}, {"groupId": "OG001", "value": "-0.0067", "spread": "0.00323"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=134, Met N=134", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0030", "spread": "0.00306"}, {"groupId": "OG001", "value": "-0.0065", "spread": "0.00304"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4584", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0033", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0122", "ciUpperLimit": "0.0055"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4039", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0035", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0118", "ciUpperLimit": "0.0048"}]}, {"type": "PRIMARY", "title": "Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed=the full analysis set (FAS). The FAS included randomized subjects who took at least 1 dose of randomized medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. Last Observation Carried Forward was used for 16 week analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change in LDL-C", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.70", "spread": "2.054"}, {"groupId": "OG001", "value": "-13.89", "spread": "2.088"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-15.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.07", "ciUpperLimit": "-10.11"}]}, {"type": "SECONDARY", "title": "Change in Plasma Glucose Area Under the Curve (0 to 120 Minutes) From the Baseline Glucose Tolerance Test (GTT) to the 16 Week GTT", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL*hr", "timeFrame": "Baseline vs. 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "114"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-67.10", "spread": "6.305"}, {"groupId": "OG001", "value": "-77.56", "spread": "6.266"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=127, Met N=124", "categories": [{"measurements": [{"groupId": "OG000", "value": "-60.34", "spread": "6.460"}, {"groupId": "OG001", "value": "-71.88", "spread": "6.524"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2289", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-27.53", "ciUpperLimit": "6.62"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1997", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-11.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.22", "ciUpperLimit": "6.14"}]}, {"type": "SECONDARY", "title": "Percent Change of Various Calculated Lipid Parameters When Given as Initial Therapy to Drug-na\u00efve, Diabetic From Baseline to 16 Weeks Subjects", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}, {"id": "OG002", "title": "Type 2 Diabetes Group: Placebo + Metformin (LOCF)", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG003", "title": "Type 2 Diabetes Group:Colesevelam+Metformin(LOCF)", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}, {"groupId": "OG002", "value": "133"}, {"groupId": "OG003", "value": "129"}]}], "classes": [{"title": "Calculated Total Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.67"}, {"groupId": "OG001", "value": "14.48"}, {"groupId": "OG002", "value": "0.99"}, {"groupId": "OG003", "value": "15.11"}]}]}, {"title": "Calc.Very Low Density Lipoprotein Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.48"}, {"groupId": "OG001", "value": "30.28"}, {"groupId": "OG002", "value": "6.62"}, {"groupId": "OG003", "value": "31.34"}]}]}, {"title": "Calculated High Density Lipoprotein-Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.51"}, {"groupId": "OG001", "value": "17.86"}, {"groupId": "OG002", "value": "8.70"}, {"groupId": "OG003", "value": "17.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Calculated Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0144", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "12.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.57", "ciUpperLimit": "23.05"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Calculated Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0037", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "14.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.63", "ciUpperLimit": "23.61"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Calculated Very Low Density Lipoprotein Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0060", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "22.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.59", "ciUpperLimit": "39.00"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Calculated Very Low Density Lipoprotein Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0013", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "24.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.71", "ciUpperLimit": "39.73"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Calculated High Density Lipoprotein-Cholesterol", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "8.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.71", "ciUpperLimit": "13.00"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Calculated High Density Lipoprotein-Cholesterol", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "8.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.27", "ciUpperLimit": "13.11"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving 2-Hr. Post Meal Glucose Goal of <180 mg/dL When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to Week 16", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to Week 16", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.2"}, {"groupId": "OG001", "value": "41.6"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=95, Met N=97", "categories": [{"measurements": [{"groupId": "OG000", "value": "37.9"}, {"groupId": "OG001", "value": "41.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8804", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "2.34"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5525", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.73", "ciUpperLimit": "2.60"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5648", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3170", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving Hs-C-Reactive Protein Goal of <2.0 mg/L When Given to Drug-na\u00efve, Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevelam placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colesevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "82"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.8"}, {"groupId": "OG001", "value": "22.0"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=91, Met N=90", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.8"}, {"groupId": "OG001", "value": "20.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9008", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "4.06"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9035", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.60", "ciUpperLimit": "3.37"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2874", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4344", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent Change in Low Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed=the full analysis set (FAS). The FAS included randomized subjects who took at least 1 dose of randomized medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The total treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg once daily. The total treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.74", "spread": "1.888"}, {"groupId": "OG001", "value": "-17.88", "spread": "1.921"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.39", "spread": "2.191"}, {"groupId": "OG001", "value": "-15.08", "spread": "2.209"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.61", "ciUpperLimit": "-14.63"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-17.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.24", "ciUpperLimit": "-11.69"}]}, {"type": "SECONDARY", "title": "Percent Change in Non-High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.50", "spread": "1.433"}, {"groupId": "OG001", "value": "-10.98", "spread": "1.461"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.20", "spread": "1.850"}, {"groupId": "OG001", "value": "-9.08", "spread": "1.867"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=104, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.69", "spread": "1.739"}, {"groupId": "OG001", "value": "-8.37", "spread": "1.770"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-12.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.26", "ciUpperLimit": "-8.69"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-10.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.15", "ciUpperLimit": "-5.41"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.69", "ciUpperLimit": "-4.42"}]}, {"type": "SECONDARY", "title": "Percent Change in High Density Lipoprotein-Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.12", "spread": "1.398"}, {"groupId": "OG001", "value": "2.85", "spread": "1.433"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.42", "spread": "1.580"}, {"groupId": "OG001", "value": "3.57", "spread": "1.601"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=104, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.06", "spread": "1.447"}, {"groupId": "OG001", "value": "3.56", "spread": "1.481"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0357", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "3.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "7.66"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6878", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.01", "ciUpperLimit": "3.31"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7972", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.37", "ciUpperLimit": "3.36"}]}, {"type": "SECONDARY", "title": "Percent Change in Total Cholesterol in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.77", "spread": "1.169"}, {"groupId": "OG001", "value": "-8.15", "spread": "1.206"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.66", "spread": "1.519"}, {"groupId": "OG001", "value": "-6.59", "spread": "1.536"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=104, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.22", "spread": "1.422"}, {"groupId": "OG001", "value": "-6.01", "spread": "1.452"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.02", "ciUpperLimit": "-5.80"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.25", "ciUpperLimit": "-4.26"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.03", "ciUpperLimit": "-3.44"}]}, {"type": "SECONDARY", "title": "Percent Change in Apolipoprotein A-1 in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-.032", "spread": "1.150"}, {"groupId": "OG001", "value": "3.18", "spread": "1.190"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=89, Col N=94", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.53", "spread": "1.312"}, {"groupId": "OG001", "value": "5.67", "spread": "1.323"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=102, Col N=102", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.68", "spread": "1.205"}, {"groupId": "OG001", "value": "5.46", "spread": "1.232"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0257", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "3.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.43", "ciUpperLimit": "6.57"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2238", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.32", "ciUpperLimit": "5.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2763", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "1.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.44", "ciUpperLimit": "4.99"}]}, {"type": "SECONDARY", "title": "Percent Change in Apolipoprotein B in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.22", "spread": "1.435"}, {"groupId": "OG001", "value": "-8.62", "spread": "1.487"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=89, Col N=94", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.67", "spread": "1.788"}, {"groupId": "OG001", "value": "-8.00", "spread": "1.807"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=102, Col N=102", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "1.648"}, {"groupId": "OG001", "value": "-7.52", "spread": "1.685"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.68", "ciUpperLimit": "-5.98"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.40", "ciUpperLimit": "-3.94"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.50", "ciUpperLimit": "-3.68"}]}, {"type": "SECONDARY", "title": "Percent Change in Apolipoprotein CIII in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.91", "spread": "3.301"}, {"groupId": "OG001", "value": "17.71", "spread": "3.043"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=88, Col N=91", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.31", "spread": "5.126"}, {"groupId": "OG001", "value": "20.89", "spread": "5.231"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=100, Col N=102", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.38", "spread": "4.627"}, {"groupId": "OG001", "value": "19.83", "spread": "4.611"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0007", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "13.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.87", "ciUpperLimit": "21.74"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0901", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "11.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.83", "ciUpperLimit": "24.99"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0918", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a", "paramType": "Mean Difference (Final Values)", "paramValue": "10.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.71", "ciUpperLimit": "22.62"}]}, {"type": "SECONDARY", "title": "Percent Change in Triglycerides in Pre-Diabetic Subjects From Baseline to 8, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-6.95", "upperLimit": "7.69"}, {"groupId": "OG001", "value": "16.57", "lowerLimit": "4.94", "upperLimit": "25.83"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.61", "lowerLimit": "-10.46", "upperLimit": "5.21"}, {"groupId": "OG001", "value": "5.91", "lowerLimit": "-0.67", "upperLimit": "13.27"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=104, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.35", "lowerLimit": "-9.85", "upperLimit": "5.66"}, {"groupId": "OG001", "value": "5.91", "lowerLimit": "0.00", "upperLimit": "13.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "pValueComment": "P-Value is from the non-parametric ANCOVA stratified by country", "statisticalMethod": "ANCOVA", "statisticalComment": "Non-parametric", "paramType": "Median Difference (Final Values)", "paramValue": "15.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.27", "ciUpperLimit": "25.83", "estimateComment": "The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "pValueComment": "P-Value is from the non-parametric ANCOVA stratified by country", "statisticalMethod": "ANCOVA", "statisticalComment": "Non-parametric", "paramType": "Median Difference (Final Values)", "paramValue": "16.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.33", "ciUpperLimit": "26.02", "estimateComment": "The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0009", "pValueComment": "P-Value is from the non-parametric ANCOVA stratified by country", "statisticalMethod": "ANCOVA", "statisticalComment": "Non-parametric", "paramType": "Median Difference (Final Values)", "paramValue": "14.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.11", "ciUpperLimit": "23.84", "estimateComment": "The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses."}]}, {"type": "SECONDARY", "title": "Percent Change in Hs-C-Reactive Protein in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.04", "lowerLimit": "-34.62", "upperLimit": "23.79"}, {"groupId": "OG001", "value": "-13.43", "lowerLimit": "-47.53", "upperLimit": "26.39"}]}]}, {"title": "Baseline to16 LOCF: Pla N=102, Col N=101", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.24", "lowerLimit": "-35.78", "upperLimit": "21.80"}, {"groupId": "OG001", "value": "-14.12", "lowerLimit": "-46.48", "upperLimit": "20.93"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6523", "pValueComment": "P-Value was from the non-parametric ANCOVA stratified by country", "statisticalMethod": "ANCOVA", "statisticalComment": "Non-parametric", "paramType": "Median Difference (Final Values)", "paramValue": "-3.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.50", "ciUpperLimit": "10.32", "estimateComment": "The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3934", "pValueComment": "P-Value was from the non-parametric ANCOVA stratified by country", "statisticalMethod": "ANCOVA", "statisticalComment": "Non-parametric", "paramType": "Median Difference (Final Values)", "paramValue": "-4.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.51", "ciUpperLimit": "8.77", "estimateComment": "The median difference was calculated using Hodges-Lehmann point estimates and corresponding 95% confidence interval was constructed using the method of Moses."}]}, {"type": "SECONDARY", "title": "Level of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. These 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nmol/L", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}, {"id": "OG002", "title": "Pre-Diabetes Group: Placebo (LOCF)", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG003", "title": "Pre-Diabetes Group: Colesevelam (LOCF)", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "99"}, {"groupId": "OG003", "value": "99"}]}], "classes": [{"title": "Total Very Low Density Lipoprotein (VLDL) Particle", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.83", "spread": "3.363"}, {"groupId": "OG001", "value": "1.92", "spread": "3.337"}, {"groupId": "OG002", "value": "0.72", "spread": "3.132"}, {"groupId": "OG003", "value": "2.25", "spread": "3.149"}]}]}, {"title": "Large VLDL Chylomicron Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-.80", "spread": "0.459"}, {"groupId": "OG001", "value": "1.64", "spread": "0.453"}, {"groupId": "OG002", "value": "-0.86", "spread": "0.424"}, {"groupId": "OG003", "value": "1.53", "spread": "0.426"}]}]}, {"title": "Medium VLDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.56", "spread": "2.004"}, {"groupId": "OG001", "value": "6.59", "spread": "1.986"}, {"groupId": "OG002", "value": "1.15", "spread": "1.890"}, {"groupId": "OG003", "value": "6.40", "spread": "1.895"}]}]}, {"title": "Small VLDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.15", "spread": "1.967"}, {"groupId": "OG001", "value": "-6.34", "spread": "1.951"}, {"groupId": "OG002", "value": "0.52", "spread": "1.837"}, {"groupId": "OG003", "value": "-5.73", "spread": "1.844"}]}]}, {"title": "Total Low Density Lipoprotein (LDL) Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.7", "spread": "38.15"}, {"groupId": "OG001", "value": "-135.2", "spread": "37.83"}, {"groupId": "OG002", "value": "-25.7", "spread": "35.97"}, {"groupId": "OG003", "value": "-138.4", "spread": "36.15"}]}]}, {"title": "Intermediate Density Lipoprotein (LDL) Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.9", "spread": "5.71"}, {"groupId": "OG001", "value": "-15.3", "spread": "5.69"}, {"groupId": "OG002", "value": "-14.7", "spread": "5.37"}, {"groupId": "OG003", "value": "-17.0", "spread": "5.41"}]}]}, {"title": "Large LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.3", "spread": "29.20"}, {"groupId": "OG001", "value": "27.6", "spread": "28.99"}, {"groupId": "OG002", "value": "91.3", "spread": "26.79"}, {"groupId": "OG003", "value": "27.5", "spread": "26.93"}]}]}, {"title": "Small LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-110.9", "spread": "44.15"}, {"groupId": "OG001", "value": "-148.6", "spread": "43.79"}, {"groupId": "OG002", "value": "-102.5", "spread": "41.72"}, {"groupId": "OG003", "value": "-149.4", "spread": "41.94"}]}]}, {"title": "Medium Small LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.5", "spread": "9.02"}, {"groupId": "OG001", "value": "-28.2", "spread": "8.95"}, {"groupId": "OG002", "value": "-21.5", "spread": "8.48"}, {"groupId": "OG003", "value": "-28.3", "spread": "8.52"}]}]}, {"title": "Very Small LDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-78.3", "spread": "35.60"}, {"groupId": "OG001", "value": "-120.3", "spread": "35.32"}, {"groupId": "OG002", "value": "-81.0", "spread": "33.68"}, {"groupId": "OG003", "value": "-121.0", "spread": "33.86"}]}]}, {"title": "Total High Density Lipoprotein (HDL) Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "spread": "0.456"}, {"groupId": "OG001", "value": "0.28", "spread": "0.452"}, {"groupId": "OG002", "value": "0.38", "spread": "0.428"}, {"groupId": "OG003", "value": "0.28", "spread": "0.430"}]}]}, {"title": "Large HDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.51", "spread": "0.211"}, {"groupId": "OG001", "value": "1.09", "spread": "0.210"}, {"groupId": "OG002", "value": "0.53", "spread": "0.197"}, {"groupId": "OG003", "value": "1.10", "spread": "0.198"}]}]}, {"title": "Medium HDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.335"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.334"}, {"groupId": "OG002", "value": "-0.24", "spread": "0.310"}, {"groupId": "OG003", "value": "-0.05", "spread": "0.312"}]}]}, {"title": "Small HDL Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "0.475"}, {"groupId": "OG001", "value": "-0.77", "spread": "0.471"}, {"groupId": "OG002", "value": "0.10", "spread": "0.450"}, {"groupId": "OG003", "value": "-0.75", "spread": "0.453"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Total VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9838", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.66", "ciUpperLimit": "8.84"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Total VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7157", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "1.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.73", "ciUpperLimit": "9.79"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Large VLDL Chylomicron Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.25", "ciUpperLimit": "3.63"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Large VLDL Chylomicron Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "2.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.27", "ciUpperLimit": "3.51"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Medium VLDL Chylomicron Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0577", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "5.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "10.24"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Medium VLDL Chylomicron Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0390", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "5.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "10.22"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Small VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0044", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.61", "ciUpperLimit": "-2.37"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Small VLDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0118", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.09", "ciUpperLimit": "-1.40"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Total Low Density Lipoprotein (LDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0293", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-110.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-209.9", "ciUpperLimit": "-11.3"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Total Low Density Lipoprotein (LDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0202", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-112.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-207.6", "ciUpperLimit": "-17.8"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Intermediate Density Lipoprotein (LDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9629", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.2", "ciUpperLimit": "14.5"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Intermediate Density Lipoprotein (LDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7485", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.5", "ciUpperLimit": "11.9"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Large LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1007", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-63.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-139.7", "ciUpperLimit": "12.5"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Large LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0768", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-63.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-134.6", "ciUpperLimit": "6.9"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4143", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-47.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-162.7", "ciUpperLimit": "67.3"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4020", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-46.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-157.1", "ciUpperLimit": "63.3"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Medium Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6378", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.1", "ciUpperLimit": "17.9"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Medium Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5528", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.1", "ciUpperLimit": "15.6"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Very Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3730", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-42.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-134.8", "ciUpperLimit": "50.8"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Very Small LDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3764", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-40.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-129.0", "ciUpperLimit": "49.0"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Total High Density Lipoprotein (HDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9807", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.20", "ciUpperLimit": "1.17"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Total High Density Lipoprotein (HDL) Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8615", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.23", "ciUpperLimit": "1.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Large HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0364", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "1.14"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Large HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0340", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "1.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Medium HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6587", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.68", "ciUpperLimit": "1.07"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Medium HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6554", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "1.00"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Small HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1957", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.06", "ciUpperLimit": "0.42"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Small HDL Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1622", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.03", "ciUpperLimit": "0.34"}]}, {"type": "SECONDARY", "title": "Particle Size of Various Lipoprotein Particles in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "nm", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}, {"id": "OG002", "title": "Pre-Diabetes Group: Placebo (LOCF)", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG003", "title": "Pre-Diabetes Group: Colesevelam (LOCF)", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "99"}, {"groupId": "OG003", "value": "99"}]}], "classes": [{"title": "Very Low Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.85", "spread": "0.956"}, {"groupId": "OG001", "value": "4.15", "spread": "0.948"}, {"groupId": "OG002", "value": "-1.43", "spread": "0.877"}, {"groupId": "OG003", "value": "3.89", "spread": "0.883"}]}]}, {"title": "Low Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": ".23", "spread": "0.068"}, {"groupId": "OG001", "value": "0.11", "spread": "0.068"}, {"groupId": "OG002", "value": "0.23", "spread": "0.064"}, {"groupId": "OG003", "value": "0.12", "spread": "0.065"}]}]}, {"title": "High Density Lipoprotein Particles", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.026"}, {"groupId": "OG001", "value": "0.15", "spread": "0.026"}, {"groupId": "OG002", "value": "0.05", "spread": "0.024"}, {"groupId": "OG003", "value": "0.15", "spread": "0.024"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Very Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "5.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.51", "ciUpperLimit": "8.48"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Very Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "5.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.00", "ciUpperLimit": "7.63"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1742", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.30", "ciUpperLimit": "0.05"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Low Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1870", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.28", "ciUpperLimit": "0.06"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "High Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0063", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "0.16"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "High Density Lipoprotein Particles", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0020", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "0.16"}]}, {"type": "SECONDARY", "title": "Change of Various Calculated Lipid Parameters in Pre-Diabetic Subjects From Baseline to 16 Weeks", "description": "These calculated values are reported as part of an NMR analysis. The calculations are done by LipoScience, Inc., and are proprietary.", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}, {"id": "OG002", "title": "Pre-Diabetes Group: Placebo (LOCF)", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG003", "title": "Pre-Diabetes Group: Colesevelam (LOCF)", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "99"}, {"groupId": "OG003", "value": "99"}]}], "classes": [{"title": "Changes in Calculated Total Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.0", "spread": "5.97"}, {"groupId": "OG001", "value": "19.4", "spread": "5.91"}, {"groupId": "OG002", "value": "-6.4", "spread": "5.60"}, {"groupId": "OG003", "value": "18.0", "spread": "5.62"}]}]}, {"title": "Changes: Calculated Very Low Density Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "5.70"}, {"groupId": "OG001", "value": "21.7", "spread": "5.64"}, {"groupId": "OG002", "value": "-5.9", "spread": "5.34"}, {"groupId": "OG003", "value": "20.6", "spread": "5.36"}]}]}, {"title": "Changes in Calculated High Density Lipoprotein -C", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "spread": "0.75"}, {"groupId": "OG001", "value": "2.9", "spread": "0.74"}, {"groupId": "OG002", "value": "1.4", "spread": "0.69"}, {"groupId": "OG003", "value": "2.9", "spread": "0.69"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Changes in Calculated Total Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0022", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "24.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.9", "ciUpperLimit": "39.9"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Changes in Calculated Total Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0013", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "24.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.6", "ciUpperLimit": "39.1"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Changes: Calculated Very Low Density Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "26.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "11.5", "ciUpperLimit": "41.0"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Changes: Calculated Very Low Density Triglycerides", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0003", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "26.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.5", "ciUpperLimit": "40.6"}, {"groupIds": ["OG000"], "groupDescription": "Changes in Calculated High Density Lipoprotein-Cholesterol", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1257", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4", "ciUpperLimit": "3.5"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Changes in Calculated High Density Lipoprotein-Cholesterol", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1054", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.3", "ciUpperLimit": "3.3"}]}, {"type": "SECONDARY", "title": "Percent Change of HbA1c in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "96"}]}], "classes": [{"title": "Baseline to 4 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.09", "spread": "0.028"}]}]}, {"title": "Baseline to 8 weeks: Pla N=98, Col N=96", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.10", "spread": "0.026"}]}]}, {"title": "Baseline to 12 weeks: Pla N=94, Col N=94", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.026"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.027"}]}]}, {"title": "Baseline to 16 weeks: Pla N=90, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.034"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.034"}]}]}, {"title": "Baseline to 16 weeks LOCF: Pla N=106, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.030"}, {"groupId": "OG001", "value": "-0.12", "spread": "0.031"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2971", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2567", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1081", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.13", "ciUpperLimit": "0.01"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0790", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.01"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0206", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.18", "ciUpperLimit": "-0.01"}]}, {"type": "SECONDARY", "title": "Percent Change of Fasting Plasma Glucose in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 4, 8, 12, and 16 weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "97"}]}], "classes": [{"title": "Baseline to 4 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "0.95"}, {"groupId": "OG001", "value": "-3.5", "spread": "0.97"}]}]}, {"title": "Baseline to 8 weeks: Pla N=97, Col N=97", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "0.94"}, {"groupId": "OG001", "value": "-3.1", "spread": "0.95"}]}]}, {"title": "Baseline to 12 weeks: Pla N=95, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "1.11"}, {"groupId": "OG001", "value": "-2.4", "spread": "1.13"}]}]}, {"title": "Baseline to 16 weeks: Pla N=91, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "1.87"}, {"groupId": "OG001", "value": "-2.8", "spread": "1.86"}]}]}, {"title": "Baseline to 16 weeks LOCF: Pla N=106, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "1.65"}, {"groupId": "OG001", "value": "-3.1", "spread": "1.67"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0009", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.8", "ciUpperLimit": "-1.8"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1184", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.5", "ciUpperLimit": "0.5"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0615", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.8", "ciUpperLimit": "0.1"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3617", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.2", "ciUpperLimit": "2.6"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2372", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.0", "ciUpperLimit": "1.7"}]}, {"type": "SECONDARY", "title": "Percent Change of Fasting Insulin in Pre-Diabetic Subjects From Baseline to 4, 8, 12, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of change", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "93"}]}], "classes": [{"title": "Baseline to 4 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.269", "spread": "0.6651"}, {"groupId": "OG001", "value": "-0.348", "spread": "0.6769"}]}]}, {"title": "Baseline to 8 Weeks: Pla N=94, Col N=97", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.208", "spread": "0.4377"}, {"groupId": "OG001", "value": "-0.513", "spread": "0.4377"}]}]}, {"title": "Baseline to 12 Weeks: Pla N=93, Col N=93", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.848", "spread": "0.4371"}, {"groupId": "OG001", "value": "-2.066", "spread": "0.4463"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=90, Col N=94", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.063", "spread": "1.2082"}, {"groupId": "OG001", "value": "-0.497", "spread": "1.1980"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=105, Col N=102", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.019", "spread": "1.0597"}, {"groupId": "OG001", "value": "-0.512", "spread": "1.0770"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2982", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.921", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.821", "ciUpperLimit": "2.663"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2361", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.695", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.458", "ciUpperLimit": "1.848"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0413", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.218", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.388", "ciUpperLimit": "-0.049"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7858", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.434", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.583", "ciUpperLimit": "2.715"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7314", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.493", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.321", "ciUpperLimit": "2.335"}]}, {"type": "SECONDARY", "title": "Change of Fasting C-peptide Levels in Pre-Diabetic Subjects From Baseline to 16 Weeks", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.039", "spread": "0.1124"}, {"groupId": "OG001", "value": "-0.050", "spread": "0.1132"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=101, Col N=100", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.049", "spread": "0.1041"}, {"groupId": "OG001", "value": "-0.057", "spread": "0.1059"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5530", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.089", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.385", "ciUpperLimit": "0.207"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4554", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.105", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.383", "ciUpperLimit": "0.172"}]}, {"type": "SECONDARY", "title": "Change of Glucose Levels 30 Minutes Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "3.82"}, {"groupId": "OG001", "value": "-1.8", "spread": "3.71"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=96, Col N=97", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "3.60"}, {"groupId": "OG001", "value": "-2.5", "spread": "3.58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8583", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.7", "ciUpperLimit": "8.9"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7975", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.5", "ciUpperLimit": "8.1"}]}, {"type": "SECONDARY", "title": "Change of Glucose Levels 1 Hour Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "4.51"}, {"groupId": "OG001", "value": "-8.0", "spread": "4.33"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=93, Col N=98", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "4.28"}, {"groupId": "OG001", "value": "-8.6", "spread": "4.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2330", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.0", "ciPctValue": "95", "ciLowerLimit": "-18.5", "ciUpperLimit": "4.5"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1412", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.2", "ciUpperLimit": "2.8"}]}, {"type": "SECONDARY", "title": "Change of Glucose Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.9", "spread": "4.65"}, {"groupId": "OG001", "value": "-6.3", "spread": "4.65"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=98, Col N=98", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.2", "spread": "4.40"}, {"groupId": "OG001", "value": "-6.1", "spread": "4.46"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8192", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.7", "ciUpperLimit": "10.8"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7513", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.5", "ciUpperLimit": "9.7"}]}, {"type": "SECONDARY", "title": "Change of Insulin Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "uIU/mL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.563", "spread": "6.6122"}, {"groupId": "OG001", "value": "-15.472", "spread": "6.4814"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=92, Col N=94", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.784", "spread": "6.2865"}, {"groupId": "OG001", "value": "-14.954", "spread": "6.2745"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4301", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.910", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.156", "ciUpperLimit": "10.336"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5369", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.170", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.661", "ciUpperLimit": "11.321"}]}, {"type": "SECONDARY", "title": "Change of C-Peptide Levels 2 Hours Post Oral Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "93"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.447", "spread": "0.3527"}, {"groupId": "OG001", "value": "-0.598", "spread": "0.3449"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=93, Col N=96", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.581", "spread": "0.3374"}, {"groupId": "OG001", "value": "-0.551", "spread": "0.3359"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7447", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.151", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.068", "ciUpperLimit": "0.765"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9476", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "0.029", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.853", "ciUpperLimit": "0.911"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <100 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "89"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.4"}, {"groupId": "OG001", "value": "29.2"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=88, Col N=86", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.2"}, {"groupId": "OG001", "value": "29.1"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=100, Col N=94", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.0"}, {"groupId": "OG001", "value": "28.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0018", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "5.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.06", "ciUpperLimit": "13.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0019", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "4.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.89", "ciUpperLimit": "10.54"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0005", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0007", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Achieving Low Density Lipoprotein-Cholesterol of <70 mg/dL at Weeks 8, 16 in Pre-Diabetic Subjects", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 8, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"title": "Baseline to 8 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0"}, {"groupId": "OG001", "value": "11.2"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=95", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3"}, {"groupId": "OG001", "value": "7.4"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=104, Col N=103", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9"}, {"groupId": "OG001", "value": "6.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0104", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2224", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "2.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "9.39"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1990", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "2.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "9.33"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2778", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2785", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Body Weight in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "lb", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.56", "spread": "0.823"}, {"groupId": "OG001", "value": "-3.24", "spread": "0.832"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=103, Col N=101", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.63", "spread": "0.758"}, {"groupId": "OG001", "value": "-3.25", "spread": "0.779"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5353", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.84", "ciUpperLimit": "1.48"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5475", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.64", "ciUpperLimit": "1.40"}]}, {"type": "SECONDARY", "title": "Change in Waist-to-Hip Ratio in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Change in Ratio", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "96"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0059", "spread": "0.00477"}, {"groupId": "OG001", "value": "-0.0058", "spread": "0.00480"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=103, Col N=101", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0051", "spread": "0.00437"}, {"groupId": "OG001", "value": "-0.0061", "spread": "0.00447"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0678", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0116", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0241", "ciUpperLimit": "0.0009"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0585", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0112", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0228", "ciUpperLimit": "0.0004"}]}, {"type": "SECONDARY", "title": "Area Under the Curve for Plasma Glucose From 0 to 120 Minutes During the Oral Glucose Tolerance Tests in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL*hr", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "93"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.26", "spread": "6.109"}, {"groupId": "OG001", "value": "-8.27", "spread": "5.878"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=92, Col N=96", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.40", "spread": "5.791"}, {"groupId": "OG001", "value": "-9.20", "spread": "5.685"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7051", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.64", "ciUpperLimit": "12.64"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5267", "pValueComment": "P-Value is for the LS Mean Difference between treatment groups", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model includes treatment and country as fixed effects and baseline lab value as a covariate", "paramType": "Mean Difference (Final Values)", "paramValue": "-4.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.72", "ciUpperLimit": "10.13"}]}, {"type": "SECONDARY", "title": "Percent Achievement of <140 mg/dL Plasma Glucose 2 Hours Post the Oral Glucose Tolerance Test in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was >or= to 140 mg/dL From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.1"}, {"groupId": "OG001", "value": "37.3"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=61, Col N=69", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.0"}, {"groupId": "OG001", "value": "37.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5882", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.40", "ciUpperLimit": "1.83"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7098", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.44", "ciUpperLimit": "1.96"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6835", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8461", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent Achievement of <110 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 110 mg/dL From Baseline to 4, 8, 12, and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 4, 8, 12, and 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "26"}]}], "classes": [{"title": "Baseline to 4 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.2"}, {"groupId": "OG001", "value": "57.7"}]}]}, {"title": "Baseline to 8 Weeks: Pla N=34, Col N=26", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.0"}, {"groupId": "OG001", "value": "42.3"}]}]}, {"title": "Baseline to 12 Weeks: Pla N=34, Col N=26", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.9"}, {"groupId": "OG001", "value": "53.8"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=32, Col N=25", "categories": [{"measurements": [{"groupId": "OG000", "value": "56.3"}, {"groupId": "OG001", "value": "44.0"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=36, Col N=29", "categories": [{"measurements": [{"groupId": "OG000", "value": "55.6"}, {"groupId": "OG001", "value": "48.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2079", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4053", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5752", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7994", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.25", "ciUpperLimit": "2.29"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9960", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.32", "ciUpperLimit": "3.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7783", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9774", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent Achievement of <100 mg/dL Fasting Plasma Glucose in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 100 mg/dL From Baseline to 4, 8, 12 and 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 4, 8, 12 and 16 weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "63"}]}], "classes": [{"title": "Baseline to 4 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.2"}, {"groupId": "OG001", "value": "39.7"}]}]}, {"title": "Baseline to 8 Weeks: Pla N=68, Col N=64", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.1"}, {"groupId": "OG001", "value": "29.7"}]}]}, {"title": "Baseline to 12 Weeks: Pla N=66, Col N=65", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.7"}, {"groupId": "OG001", "value": "33.8"}]}]}, {"title": "Baseline to 16 Weeks: Pla N=62, Col N=64", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.4"}, {"groupId": "OG001", "value": "40.6"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=73, Col N=68", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.3"}, {"groupId": "OG001", "value": "39.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 4 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 8 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4058", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 12 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0254", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1499", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.74", "ciUpperLimit": "3.55"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0420", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "2.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "4.45"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2240", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0593", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent Achievement of <140 mg/dL Plasma Glucose Post 2 Hour Glucose Tolerance Test and Fasting Plasma Glucose <110 mg/dL in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "72"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.9"}, {"groupId": "OG001", "value": "30.6"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=69, Col N=75", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.2"}, {"groupId": "OG001", "value": "32.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4794", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.31", "ciUpperLimit": "1.40"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6667", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "0.75", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "1.55"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2768", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4395", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent Achievement of Hs-C-Reactive Protein <2.0 mg/L in Pre-Diabetic Subjects Whose Corresponding Baseline Value Was > or = to 2.0 mg/L From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "60"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.0"}, {"groupId": "OG001", "value": "21.7"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=78, Col N=65", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.8"}, {"groupId": "OG001", "value": "20.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1375", "pValueComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "2.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.89", "ciUpperLimit": "6.64"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1996", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "P-Value for comparing percentages was from the Cochran-Mantel-Haenszel test stratified by country.", "paramType": "Odds Ratio (OR)", "paramValue": "2.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.85", "ciUpperLimit": "5.82"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0829", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Baseline to 16 Weeks LOCF", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1037", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Contained treatment and country as factors and baseline lab value as a covariate", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Percent of Subjects Meeting Type 2 Diabetes Criteria (Fasting Plasma Glucose >or= to 126 mg/dL or Plasma Glucose >or= to 200 mg/dL Post 2 Hr Glucose Tolerance Test in Pre-Diabetic Subjects From Baseline to 16 Weeks", "populationDescription": "The No. analyzed equals the full analysis set (FAS). The FAS included all randomized subjects who took at least 1 dose of randomized study medication, had a baseline and at least 1 post-baseline efficacy variable measurement. The FAS was used for the summary and analysis of all efficacy variables. The 16 week analyses are both LOCF and no LOCF.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of participants", "timeFrame": "Baseline to 16 Weeks", "groups": [{"id": "OG000", "title": "Pre-Diabetes Group: Placebo", "description": "This group received 6 matching colesevelam placebo tablets/day. The treatment duration was 16 weeks."}, {"id": "OG001", "title": "Pre-Diabetes Group: Colesevelam", "description": "This group received 6 colesevelam tablets 625 mg/day. The treatment duration was 16 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "81"}]}], "classes": [{"title": "Baseline to 16 Weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.1"}, {"groupId": "OG001", "value": "11.1"}]}]}, {"title": "Baseline to 16 Weeks LOCF: Pla N=87, Col N=84", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.3"}, {"groupId": "OG001", "value": "10.7"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Adverse events were collected from the signing of the informed consent form until the end of the study + a follow up period (until the AE resolved or stabilized). This period of time equals about 17.5 weeks.", "description": "AEs were noted by investigator or reported by subject. Nature, duration, remedial action, and severity of AE were recorded. Lab abnormalities were AEs if they needed intervention, further investigation, led to a change in medication, or were part of a larger disease process. Only 107 in the prediabetes colesevelam group because 1 did not take drug.", "eventGroups": [{"id": "EG000", "title": "Type 2 Diabetes Group: Placebo + Metformin", "description": "This group received 6 matching colesevalm placebo tablets/day + open-label metformin. The dose of metformin depended on the participant's tolerability. This treatment duration was 16 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 141, "otherNumAffected": 97, "otherNumAtRisk": 141}, {"id": "EG001", "title": "Type 2 Diabetes Group: Colesevelam + Metformin", "description": "This group received 6 colevevelam tablets 625 mg once daily + open-label metformin once a day. The dose of metformin depended on the participant's tolerance for the drug. This treatment duration was 16 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 145, "otherNumAffected": 97, "otherNumAtRisk": 141}, {"id": "EG002", "title": "Pre-diabetic Group: Placebo", "description": "This group was given 6 placebo tablets once a day. They matched the colesevelam tablets. This treatment duration was 16 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 108, "otherNumAffected": 63, "otherNumAtRisk": 108}, {"id": "EG003", "title": "Pre-diabetic Group: Colesevelam", "description": "This group was given 6 colesevelam tablets, 625mg, once a day. This treatment duration was 16 weeks.", "seriousNumAffected": 2, "seriousNumAtRisk": 107, "otherNumAffected": 57, "otherNumAtRisk": 107}], "seriousEvents": [{"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Cystocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Erectile dysfunction", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Lung squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Polycystic Ovaries", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 145}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 107}]}], "otherEvents": [{"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Abdominal pain uppper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 107}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 107}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 107}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Anorexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Dyslipidemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Hypoglycemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 107}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 107}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 107}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 107}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Anxiety", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 107}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 141}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 141}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 108}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 107}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The following language is employed: \"If identified by DSI, any of DSI's confidential information as defined herein shall be deleted...Nothing in this publication section shall be taken as giving DSI and right of editorial control over any publication prepared by the Study Site.\""}, "pointOfContact": {"title": "John Raia, Senior Director Professional Affairs", "organization": "Daiichi Sankyo, Inc.", "email": "jraia@dsi.com", "phone": "(973) 944-2683"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}, {"id": "D000006937", "term": "Hypercholesterolemia"}, {"id": "D000011236", "term": "Prediabetic State"}, {"id": "D000018149", "term": "Glucose Intolerance"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000006949", "term": "Hyperlipidemias"}, {"id": "D000050171", "term": "Dyslipidemias"}, {"id": "D000052439", "term": "Lipid Metabolism Disorders"}, {"id": "D000006943", "term": "Hyperglycemia"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M14117", "name": "Prediabetic State", "asFound": "Pre-diabetes", "relevance": "HIGH"}, {"id": "M20295", "name": "Glucose Intolerance", "asFound": "Pre-diabetes", "relevance": "HIGH"}, {"id": "M9988", "name": "Hypercholesterolemia", "asFound": "Hypercholesterolemia", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M10000", "name": "Hyperlipidemias", "relevance": "LOW"}, {"id": "M10002", "name": "Hyperlipoproteinemias", "relevance": "LOW"}, {"id": "M26181", "name": "Dyslipidemias", "relevance": "LOW"}, {"id": "M27029", "name": "Lipid Metabolism Disorders", "relevance": "LOW"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069472", "term": "Colesevelam Hydrochloride"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M441", "name": "Colesevelam Hydrochloride", "asFound": "Inspiration", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}]}}, "hasResults": true}